CN111875585B - 一类激酶抑制剂 - Google Patents

一类激酶抑制剂 Download PDF

Info

Publication number
CN111875585B
CN111875585B CN202010883613.XA CN202010883613A CN111875585B CN 111875585 B CN111875585 B CN 111875585B CN 202010883613 A CN202010883613 A CN 202010883613A CN 111875585 B CN111875585 B CN 111875585B
Authority
CN
China
Prior art keywords
methyl
amino
ethyl
pyrimidin
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010883613.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111875585A (zh
Inventor
李同双
赵兴东
田强
张卫鹏
刘洪彬
王宪龙
谭浩瀚
谭锐
刘启洪
姜立花
刘研新
令狐莉
林敏�
孙婧
王为波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Medicine Polytron Technologies Inc
Original Assignee
Shanghai Allist Medicine Polytron Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54832920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111875585(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Allist Medicine Polytron Technologies Inc filed Critical Shanghai Allist Medicine Polytron Technologies Inc
Priority to CN202010883613.XA priority Critical patent/CN111875585B/zh
Publication of CN111875585A publication Critical patent/CN111875585A/zh
Application granted granted Critical
Publication of CN111875585B publication Critical patent/CN111875585B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202010883613.XA 2014-06-12 2015-06-12 一类激酶抑制剂 Active CN111875585B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010883613.XA CN111875585B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462011109P 2014-06-12 2014-06-12
US62/011109 2014-06-12
US201462090360P 2014-12-11 2014-12-11
US62/090360 2014-12-11
CN202010883613.XA CN111875585B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂
PCT/CN2015/081332 WO2015188777A1 (fr) 2014-06-12 2015-06-12 Inhibiteurs particuliers de protéines kinases
CN201580031253.8A CN106660993B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580031253.8A Division CN106660993B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂

Publications (2)

Publication Number Publication Date
CN111875585A CN111875585A (zh) 2020-11-03
CN111875585B true CN111875585B (zh) 2023-06-23

Family

ID=54832920

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010883613.XA Active CN111875585B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂
CN201580031253.8A Active CN106660993B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂
CN202010883627.1A Active CN111892579B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580031253.8A Active CN106660993B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂
CN202010883627.1A Active CN111892579B (zh) 2014-06-12 2015-06-12 一类激酶抑制剂

Country Status (2)

Country Link
CN (3) CN111875585B (fr)
WO (1) WO2015188777A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN117069700A (zh) * 2014-10-11 2023-11-17 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
RS59900B1 (sr) * 2014-10-13 2020-03-31 Yuhan Corp Jedinjenja i kompozicije za moduliranje aktivnosti egfr mutant kinaze
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016105525A2 (fr) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Nouvelles pyrimidines en tant qu'inhibiteurs d'egfr et procédés de traitement de troubles
CN106117185B (zh) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
AU2016379292B2 (en) 2015-12-24 2021-03-25 Kyowa Kirin Co., Ltd. α, β unsaturated amide compound
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
KR20180105161A (ko) * 2016-01-07 2018-09-27 씨에스 파마테크 리미티드 Egfr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제
CN106279160B (zh) * 2016-03-18 2017-09-26 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
AR110038A1 (es) 2016-05-26 2019-02-20 Kalyra Pharmaceuticals Inc Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
CN106957304B (zh) * 2017-04-25 2017-12-01 孔令廷 一种石墨烯负载FeCl3催化剂的制备方法及其在制备抗癌药物中间体的用途
WO2018235926A1 (fr) 2017-06-23 2018-12-27 協和発酵キリン株式会社 COMPOSÉ AMIDE α, β-INSATURÉ
CN107266437B (zh) 2017-07-19 2019-08-30 海南越康生物医药有限公司 N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法
SMT202300339T1 (it) 2017-07-28 2023-11-13 Yuhan Corp Procedimento per preparare n-(5-((4-(4-((dimetilammino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)ammino)-4-metossi-2-morfolinofenil)acrilammide facendo reagire l’ammina corrispondente con un cloruro di 3-alo-propionile
CN107827875B (zh) * 2017-09-25 2021-07-09 文韬创新药物研究（北京）有限责任公司 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用
AU2019209475A1 (en) 2018-01-16 2020-08-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2019209470A1 (en) 2018-01-16 2020-08-13 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN110857292A (zh) * 2018-08-22 2020-03-03 上海艾力斯医药科技有限公司 一种egfr激酶抑制剂及其制备方法和应用
CA3118330A1 (fr) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
CN110041302B (zh) * 2019-03-01 2021-11-30 南方医科大学 2-氨基-4-取代吡啶衍生物及其合成方法和应用
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
JOP20210304A1 (ar) * 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
JP2023052711A (ja) * 2020-03-04 2023-04-12 国立研究開発法人理化学研究所 化合物を放出する方法
CN111303123B (zh) * 2020-03-31 2021-08-31 南京雷正医药科技有限公司 2-(2,4,5-取代苯胺基)嘧啶化合物及其应用
AU2022297453A1 (en) * 2021-06-22 2024-01-04 Crimson Biopharm Inc. (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors
CN115701429B (zh) * 2021-08-02 2024-03-12 上海和誉生物医药科技有限公司 4-(1h-吲哚-1-基)嘧啶-2-氨基衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102083800A (zh) * 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
CN103702990A (zh) * 2011-07-27 2014-04-02 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102083800A (zh) * 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
CN103702990A (zh) * 2011-07-27 2014-04-02 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R.B.西尔弗曼.生物电子等排.《有机药物化学》.2008, *
Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR);AstraZeneca 等;《Journal of Medicinal Chemistry》;20130809;摘要、表1,4-7 *

Also Published As

Publication number Publication date
CN111892579B (zh) 2023-07-25
CN111875585A (zh) 2020-11-03
WO2015188777A1 (fr) 2015-12-17
CN106660993B (zh) 2020-09-11
CN106660993A (zh) 2017-05-10
CN111892579A (zh) 2020-11-06

Similar Documents

Publication Publication Date Title
CN111875585B (zh) 一类激酶抑制剂
JP6570001B2 (ja) Ａｌｋキナーゼ阻害剤
CN110372720B (zh) 一类激酶抑制剂
US10022374B2 (en) Certain protein kinase inhibitors
JP5001179B2 (ja) 化学物質
JP5415403B2 (ja) ９−（ピラゾール−３−イル）−９ｈ−プリン−２−アミンおよび３−（ピラゾール−３−イル）−３ｈ−イミダゾ［４，５−ｂ］ピリジン−５−アミン誘導体および癌の処置のためのそれらの使用
CN106132963B (zh) (5,6-二氢)嘧啶并[4,5-e]吲嗪
AU2020255100A1 (en) N-heteroaromatic amide derivatives for treatment of cancer
CN107892684B (zh) 喹唑啉衍生物及其药物组合物，以及作为药物的用途
CN107207441B (zh) 蛋白激酶抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210712

Address after: 201210 5th floor, building 1, 1118 Halley Road, 1227 zhangheng Road, Pudong New Area pilot Free Trade Zone, Shanghai

Applicant after: Shanghai ALLIST medicine Polytron Technologies Inc.

Address before: Room 512, A Building, 1289 Yishan Road, Xuhui District, Shanghai, 2003

Applicant before: CHINA SHANGHAI FOCHON PHARMACEUTICAL Co.,Ltd.

Applicant before: FOCHON PHARMACEUTICALS, Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: No. 268 Lingxiaohua Road, Zhoupu Town, Pudong New Area, Shanghai, 201318

Applicant after: Shanghai ALLIST medicine Polytron Technologies Inc.

Address before: 201210 5th floor, building 1, 1118 Halley Road, 1227 zhangheng Road, Pudong New Area pilot Free Trade Zone, Shanghai

Applicant before: Shanghai ALLIST medicine Polytron Technologies Inc.

GR01 Patent grant
GR01 Patent grant